Lornoxicam

證據等級: L5

預測適應症: 10 個

Lornoxicam: From Pain and Inflammatory Conditions to Rheumatoid Arthritis

One-Sentence Summary

Lornoxicam is an oxicam-class NSAID (non-steroidal anti-inflammatory drug) with analgesic, anti-inflammatory, and antipyretic properties, established for managing pain and inflammatory conditions. The TxGNN model predicts it may be effective for Rheumatoid Arthritis as its top-ranked indication (score 99.90%), supported by strong mechanistic rationale — COX-1/COX-2 inhibition reduces synovial PGE2, a core pathway targeted by approved oxicam-class drugs in RA. However, no dedicated clinical trials or publications for this specific drug-indication pair were identified, placing current evidence at Level L4 (mechanistic/class-analogy only).

Quick Overview

Item	Content
Original Indication	Pain and inflammatory conditions (analgesic and anti-inflammatory use)
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	99.90%
Evidence Level	L4
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the queried data sources. Based on known pharmacological information, Lornoxicam (also known as chlortenoxicam) is a member of the oxicam subclass of NSAIDs. It inhibits both COX-1 and COX-2 cyclooxygenase enzymes, thereby suppressing prostaglandin synthesis — particularly PGE2 — which mediates pain sensitization and tissue inflammation. A notable pharmacokinetic feature is its relatively short elimination half-life of 3–5 hours, in contrast to longer-acting oxicams such as Piroxicam, which may offer tolerability advantages in chronic dosing scenarios.

Rheumatoid arthritis is a systemic autoimmune disease characterized by persistent synovial inflammation, in which PGE2 overproduction by activated macrophages and fibroblast-like synoviocytes drives joint swelling, pain, and structural damage. NSAIDs, including oxicam-class agents, are standard first-line symptomatic therapy in RA. Crucially, two structurally and mechanistically related oxicam drugs — Meloxicam (selective COX-2 preference) and Piroxicam (COX-1/2 non-selective) — carry regulatory approvals for RA in multiple markets, providing direct pharmacological class precedent for Lornoxicam’s predicted activity in this indication.

The TxGNN prediction is therefore mechanistically well-grounded: the knowledge graph correctly identifies Lornoxicam as belonging to a drug class with established RA utility. The absence of dedicated Lornoxicam-RA clinical trial data most likely reflects historical commercial positioning — Lornoxicam has primarily been developed for acute pain settings (post-operative analgesia, musculoskeletal pain) in markets where it is approved, and long-term RA trials have not been pursued.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Lornoxicam currently has no registered products with CDSCO in India. The drug is not marketed.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic connection between Lornoxicam and rheumatoid arthritis is pharmacologically coherent and supported by class-level analogy (Meloxicam, Piroxicam both oxicam-class, both RA-approved), but no Lornoxicam-specific clinical trial or publication evidence for RA was identified, and the drug carries zero registrations in India — making a go decision premature without foundational data collection.

To proceed, the following is needed:

Retrieve full MOA details and safety profile from DrugBank (DB06725) to complete the mechanistic and safety assessment
Obtain CDSCO-equivalent package insert or SmPC data for key warnings, contraindications, and drug-drug interactions (DDI file error noted in query log — DDInter database path missing)
Conduct targeted literature search for Lornoxicam in rheumatoid arthritis and related inflammatory arthropathies (e.g., osteoarthritis, ankylosing spondylitis), as indexed studies may exist outside the current PubMed query scope
Benchmark against approved oxicam comparators in RA (Meloxicam 7.5–15 mg, Piroxicam 20 mg) to assess whether Lornoxicam’s shorter half-life (3–5 h) provides a clinical or safety differentiation rationale
Map India CDSCO regulatory pathway for a new RA indication — assess whether a bridging study or bibliographic application is feasible given class-level precedent
Note: Evidence Pack also captured migraine disorder (rank #3, L2 evidence, 1 completed Phase 2 RCT [NCT00293657, n=150]) as a higher-evidence repurposing candidate worth parallel evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.